Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

C018 - Dermatology Review: General and Cosmetic

Saturday, February 17; 1:00 PM - 4:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Recognize new developments in medical and cosmetic dermatology.
  • Evaluate new treatment options for dermatologic conditions, including psoriasis, eczema, and contact dermatitis.
  • Analyze and describe best practices for cosmetic dermatology.

Description

This course will comprehensively review new developments in medical, cosmetic and surgical dermatology. Innovation in diagnosis and treatment of common dermatologic conditions, such as skin cancer, actinic keratosis, psoriasis, eczema, acne, contact dermatitis, infectious diseases in dermatology, and rosacea will be reviewed. New developments in cosmetic dermatology and best practices in surgical and cosmetic dermatology will be reviewed. Practice management, including billing, coding, electronic health records, and new payment models.

Disclosures

  • Blauvelt, Andrew, MD: AbbVie – A(H), C(H), I(Fees); Aclaris Therapeutics Inc. – A(H), C(H), I(Fees); Akros Pharma, Inc. – A(H), C(H); Allergan, Inc – A(H), C(H), I(Fees); Almirall – A(H), C(H); Amgen – A(H), C(H), I(Fees); Boehringer Ingelheim – A(H), C(H), I(Fees); Celgene – A(H), C(H), I(Fees); Dermavant Sciences – A(H), C(H), I(Fees); Dermira – A(H), C(H), I(Fees); Eli Lilly and Company – A(H), C(H), I(Fees); Galderma Laboratories, L.P. – A(H), C(H); Genentech, Inc. – A(H), C(H), I(Fees); GlaxoSmithKline – A(H), C(H), I(Fees); Janssen-Ortho Inc. – A(H), C(H), I(Fees), SP(H); Leo Pharma Inc – A(H), C(H), I(Fees); Meiji Seika Pharma Co., Ltd – A(H), C(H); Merck & Co., Inc – A(H), C(H), I(Fees); Novartis Pharmaceuticals Corp. – A(H), C(H), I(Fees); Pfizer Inc. – A(H), C(H), I(Fees); Purdue Pharma – A(H), C(H); Regeneron – A(H), C(H), I(Fees), SP(H); Sandoz, a Novartis company – A(H), C(H), I(Fees); Sanofi – A(H), C(H), SP(H); Sienna Biopharmaceuticals – A(H), C(H), I(Fees); Sun Pharmaceutical Industries Ltd. – A(H), C(H); UCB – A(H), C(H), I(Fees); Valeant Pharmaceuticals International – A(H), C(H), I(Fees); Vidac Pharma – A(H), C(H), I(Fees);
  • Ceilley, Roger I., MD: Biofrontera AG – A(H); Ferndale Laboratories, Inc. – A(H); Pfizer Inc. – A(H); Sun Pharmaceutical Industries Ltd. – A(H);
  • Cohen, David Eric, MD: Bickel Biotechnology – B(SO); Dermira – B(Fees), B(ST); Facilitation of International Dermatology Education – C(H); Ferndale Laboratories, Inc. – C(H); Medimetriks Pharmaceuticals, Inc. – C(H), C(SO); Novartis – C(H);
  • Draelos, Zoe Diana, MD: Abbott Laboratories – I(Grants/Research Funding); Actavis – I(Grants/Research Funding); AGI Dermatics – I(Grants/Research Funding); Allergan, Inc. – I(Grants/Research Funding); AmDerma Pharmaceuticals, LLC – I(Grants/Research Funding); Amgen – I(Grants/Research Funding); Amneal Pharmaceuticals, LLC – I(Grants/Research Funding); AstraZeneca – I(Grants/Research Funding); Avon Products, Inc. – I(Grants/Research Funding); Bayer – I(Grants/Research Funding); Bayer Consumer Healthcare Pharmaceuticals – I(Grants/Research Funding); Beiersdorf, Inc. – I(Grants/Research Funding); Boots – C(Grants/Research Funding); Celgene Corporation – I(Grants/Research Funding); Chattem, Inc. – I(Grants/Research Funding); Colgate-Palmolive – I(Grants/Research Funding); Dermira – I(Grants/Research Funding); Dial Corporation – I(Grants/Research Funding); Eli Lilly and Company – I(Grants/Research Funding); Elizabeth Arden – I(Grants/Research Funding); Exeltis – I(Grants/Research Funding); Galderma Laboratories, L.P. – I(Grants/Research Funding); GlaxoSmithKline – I(Grants/Research Funding); Glenmark Generics Inc. – I(Grants/Research Funding); Guthy-Renker – I(Grants/Research Funding); Helix BioMedix – I(Grants/Research Funding); Johnson & Johnson Consumer Products Company – I(Grants/Research Funding); Kao Brands – I(Grants/Research Funding); Kimberly Clark – I(Grants/Research Funding); Kythera – I(Grants/Research Funding); L'Oreal USA Inc. – I(Grants/Research Funding); La Roche-Posay Laboratoire Pharmaceutique – I(Grants/Research Funding); Lexington International LLC – I(Grants/Research Funding); Living Proof, Inc – I(Grants/Research Funding); Lumity – I(Grants/Research Funding); MakuCell, Inc. – I(Grants/Research Funding); Maruho Co., Ltd – I(Grants/Research Funding); Medicis Pharmaceutical Corporation – I(Grants/Research Funding); Merck & Co., Inc. – I(Grants/Research Funding); Merz Pharmaceuticals, LLC – I(Grants/Research Funding); Mimetica Pty. Limited – I(Grants/Research Funding); Neocutis – I(Grants/Research Funding); Neutrogena Corporation – I(Grants/Research Funding); Niadyne – I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – I(Grants/Research Funding); Nuskin – I(Grants/Research Funding); Oculus – I(Grants/Research Funding); Onset Therapeutics – I(Grants/Research Funding); Otsuka Pharmaceutical Co., Ltd. – I(Grants/Research Funding); Pacific Biosciences – I(Grants/Research Funding); Perrigo Company – I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding); Procter & Gamble Company – I(Grants/Research Funding); Promius Pharma, LLC – I(Grants/Research Funding); Quinnova Pharmaceuticals, Inc. – I(Grants/Research Funding); Ranbaxy Laboratories Limited – I(Grants/Research Funding); RECKITT BENCKISER (ESPAÑA), S.L. – I(Grants/Research Funding); Revance Therapeutics, Inc. – I(Grants/Research Funding); Revision Skincare – I(Grants/Research Funding); Signum Biosciences, Inc. – I(Grants/Research Funding); SkinMedica, Inc. – I(Grants/Research Funding); Sun Products Corporation – I(Grants/Research Funding); Suneva Medical, Inc. – I(Grants/Research Funding); Symrise – I(Grants/Research Funding); Syneron, Inc. – I(Grants/Research Funding); Taro Pharm – I(Grants/Research Funding); Teva Pharmaceuticals USA – I(Grants/Research Funding); Tolmar – I(Grants/Research Funding); Valeant Pharmaceuticals International – I(Grants/Research Funding); Vichy Laboratoires – I(Grants/Research Funding);
  • Eichenfield, Lawrence F., MD: Allergan, Inc – C(H), I(Fees); Anacor Pharmaceuticals, Inc. – C(H); Cutanea Life Sciences – C(H); Dr. Reddy – C(H); DS Laboratories – C(H); Elsevier Inc. – O(IP); Galderma Laboratories, L.P. – C(H), I(Fees); Genentech, Inc. – C(H); Kimberly Clark – I(Fees); LEO Pharma, US – C(H), I(Fees); Lilly ICOS LLC – C(H); Medimetriks Pharmaceuticals, Inc. – C(H); Novan – C(H), I(Fees); Otsuka Pharmaceutical Co., Ltd. – C(H); Pfizer Inc. – C(H); Ralexar Therapeutics, Inc – C(H); Sanofi/Regeneron – C(H), I(Fees); Tioga Pharmaceuticals, Inc. – C(H); TopMD – C(SO); Valeant Pharmaceuticals International – C(H); Valeant Pharmaceuticals North America LLC – I(Fees); Wiley-Blackwell – O(H);
  • Elewski, Boni E., MD: AbbVie – I(Grants/Research Funding); Boehringer Ingelheim – C(H), I(Grants/Research Funding); Celgene Corporation – C(H), I(Grants/Research Funding); Eli Lilly and Company – I(Grants/Research Funding); Incyte Corporation – I(Grants/Research Funding); Janssen-Ortho Inc. – I(Grants/Research Funding); LEO Laboratories Ltd (LEO Pharma) – A(H), I(Grants/Research Funding); Lilly ICOS LLC – C(H); Merck & Co., Inc – I(Grants/Research Funding); Novan – C(H); Novartis Pharmaceuticals Corp. – C(H), I(Grants/Research Funding); Pfizer Inc. – C(H), I(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – C(H), I(Grants/Research Funding); Valeant Pharmaceuticals International – C(H); Valeant Pharmaceuticals North America LLC – I(Grants/Research Funding);
  • Goldenberg, Gary, MD: AbbVie – SP(H); Allergan, Inc – C(H); Anacor Pharmaceuticals, Inc. – C(H); Bayer – SP(H); Bayer Pharmaceuticals – C(H); Castle Biosciences – SP(H); Celgene Corporation – C(H), SP(H); Dermira – A(H); Eclipse Medical – C(H); Eli Lilly and Company – C(Fees), SP(H); Galderma USA – SP(H); Genentech, Inc. – C(H); Janssen Pharmaceuticals, Inc – C(H); Leo Pharma A/S – I(Grants/Research Funding); LEO Pharma, US – C(H), SP(H); MelaSciences – C(H); Novartis Pharmaceuticals Corp. – C(H), SP(H); Pfizer Inc. – C(H); Pharmaderm – A(H), I(Grants/Research Funding), SP(H); Ranbaxy Laboratories Limited – C(H); Stiefel a GSK company – C(H), I(Grants/Research Funding); Taro Pharm – C(Fees); Teva Pharmaceuticals USA – C(Fees); Valeant Pharmaceuticals North America LLC – C(H), I(Grants/Research Funding), SP(H); Xoft – C(H);
  • Jorizzo, Joseph L., MD: Amgen – A(H); LEO Pharma, US – A(H);
  • Rigel, Darrell S., MD: Aclaris Therapeutics, Inc. – C(H); Beiersdorf, Inc. – A(H); Castle Biosciences – A(H), I(Grants/Research Funding); Derm Tech International – A(H); Foamix – B(H); LEO Pharma, US – A(H); Myriad Genetics Inc – A(H); Novartis – A(H); Ortho Dermatologics – A(H); Pierre Fabre Dermo-Cosmétique US – A(H);
  • Rohrer, Thomas E., MD: Allergan, Inc. – I(Grants/Research Funding); Candela Corporation – A(H), SP(H); Medicis Pharmaceutical Corporation – SP(H); Merz Pharmaceuticals, LLC – I(H); Pulse Biosciences – A(H); Ulthera – I(H);
  • Sadick, Neil S., MD: Allergan, Inc. – C(H), O(H); Almirall – C(H); Amgen – I(Grants/Research Funding); Carma Laboratories, Inc – O(H); Cassiopea SpA – I(Grants/Research Funding); Celgene Corporation – I(Grants/Research Funding), SP(H); Cutera, Inc. – I(Grants/Research Funding), SP(H); Cynosure, Inc. – C(H), I(Grants/Research Funding); Derm Advance – SH(SO); DS Laboratories – I(Grants/Research Funding); Eclipse Medical – O(H); Eli Lilly and Company – I(Grants/Research Funding); Endo International plc – C(H), I(Grants/Research Funding); EndyMed Medical Inc. USA – SP(H); Eternogen – C(SO); Foamix – I(Grants/Research Funding); Galderma Laboratories, L.P. – A(H), O(H); Galderma USA – I(Grants/Research Funding); Gerson Lehrman Group – C(H); Hydropeptide, LLC – I(Grants/Research Funding); Kadmon Corporation, LLC – I(Grants/Research Funding); LEO Laboratories Ltd (LEO Pharma) – I(Grants/Research Funding); Merz Aesthetics – A(H), C(H); Neostrata – I(Grants/Research Funding); Novartis – I(Grants/Research Funding); Nutraceutical Wellness, LLC. – I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding); Prescriber's Choice – O(H); Ralexar Therapeutics, Inc – I(Grants/Research Funding); Regeneron – I(Grants/Research Funding); Roche Laboratories – I(Grants/Research Funding); Slender Medical Ltd. – SH(SO); Solta Medical – O(H), SP(H); Storz Medical AG – SP(H); Valeant Pharmaceuticals International – C(H), I(Grants/Research Funding), O(H); Vanda Pharmaceuticals Inc. – I(Grants/Research Funding); Vascular Insights, LLC – SH(SO); Venus Concept – C(SO), I(Grants/Research Funding), SP(H);
  • Sobell, Jeffrey M., MD: AbbVie – A(H), I(Grants/Research Funding), SP(H); Amgen – A(H), I(Grants/Research Funding), SP(H); Celgene Corporation – A(H), I(Grants/Research Funding), SP(H); Eli Lilly and Company – A(H), I(Grants/Research Funding), SP(H); Janssen-Ortho Inc. – A(H), I(Grants/Research Funding), SP(H); Merck & Co., Inc – I(Grants/Research Funding); Novartis – C(H), I(Grants/Research Funding), SP(H); Regeneron – I(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – A(H);
Schedule
Saturday, February 17
1:00 PM
Dr. Cohen / Contact dermatitis update
1:15 PM
Dr. Rigel / Melanoma in 2018
1:30 PM
Dr. Sadick / Non-invasive body contouring
1:45 PM
Dr. Rohrer / What’s New in Laser Resurfacing
2:00 PM
Dr. Jorizzo / Update on Diagnosis and treatment of vasculitis
2:15 PM
Dr. Cohen, Dr. Rigel, Dr. Sadick, Dr. Rohrer, and Dr. Jorizzo / Q&A
2:30 PM
Dr. Eichenfield / What’s new in pediatric dermatology
2:45 PM
Dr. Ceilley / Surgical Techniques for Optimal Wound Closure
3:00 PM
Dr. Sobell / Biologics in psoriasis: 2018 and beyond
3:15 PM
Dr. Elewski / Update on diagnosis and treatment of onychomycosis
3:30 PM
Dr. Blauvelt / Treatment of atopic dermatitis in 2018
3:45 PM
Dr. Eichenfield, Dr. Sobell, Dr. Elewski, Dr. Blauvelt, and Dr. Ceilley / Q&A
Event Details
  • Date
    Saturday, February 17
  • Time
    1:00 PM - 4:00 PM
  • Location
    Room 8
  • CME Credits
    3.00
  • Type
    Ticketed
Directors/Co-Directors
Speakers
  • Andrew Blauvelt, MD, FAAD
  • Boni E. Elewski, MD, FAAD - Handout
  • Darrell S. Rigel, MD, FAAD - Handout
  • David Eric Cohen, MD, FAAD
  • Jeffrey M. Sobell, MD, FAAD - Handout
  • Joseph L. Jorizzo, MD, FAAD - Handout
  • Lawrence F. Eichenfield, MD, FAAD
  • Neil S. Sadick, MD, FAAD
  • Roger I. Ceilley, MD, FAAD
  • Thomas E. Rohrer, MD, FAAD
  • Zoe Diana Draelos, MD, FAAD - Handout